Setback for Corcept as Court Backs Teva in Korlym Generic Fight

Corcept Therapeutics announced a setback in its patent litigation against Teva Pharmaceuticals, as the U.S. Court of Appeals for the Federal Circuit upheld a lower court’s decision finding no infringement by Teva’s proposed generic version of Korlym.​

Korlym and the Patent Dispute Overview

Korlym (mifepristone) treats hyperglycemia in patients with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are ineligible for or have failed surgery.​
The drug modulates cortisol, a hormone often elevated in this rare disorder, but requires careful management when co-administered with CYP3A4 inhibitors, common in these patients to avoid excessive exposure.​

Corcept has litigated extensively to protect Korlym from generics; this case involved two patents on methods for safely dosing Korlym with such inhibitors.​
In December 2023, the Federal District Court for the District of New Jersey ruled that Teva’s marketing would not infringe these patents; the Federal Circuit affirmed this on February 19, 2026.​

Corcept’s Response

CEO Joseph K. Belanoff, M.D., expressed disappointment, noting the patents cover everyday treatment methods for Cushing’s syndrome patients.​ Corcept plans to vigorously defend its rights and is evaluating judicial review options.​

Implications

This ruling removes one legal barrier for Teva’s proposed generic Korlym, which received FDA tentative approval in 2018, though Corcept is evaluating further judicial review and other patents may remain relevant.
Corcept, focused on cortisol modulation therapies, will continue advancing its pipeline amid ongoing IP challenges.

Reference

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals, 19 February 2026, Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals – Corcept Therapeutics, Incorporated